84P Survival outcomes in stage IV small-cell lung cancer (IV-SCLC): Analysis from SEER database
ConclusionThis real world data analysis reflects that the chance of having long term survivors in SCLC is very low and that mOS has not been improved over the last years. The introduction of new therapies such as immune checkpoints opens a new opportunity for long term survival and better outcomes in this aggressive disease.Legal entity responsible for the studyRoche Farma S.A.FundingRoche Farma S.A.DisclosureJ. de Castro Carpe ño: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / C onsultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZ; Advisory / Consultancy: Pfizer; Advisory / Consultancy: PharmaMar; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda; Advis ory / Consultancy: Tesaro. M. Cobo Dols: Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZ; Advisory / Consultancy: Pfizer; Advisory / Co nsultancy: Boehringer. M. Domine Gomez: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Databases & Libraries | Employment | Legislation | Liver | Lung Cancer | Merck | Neurology | Pfizer | Small Cell Lung Cancer | Study | Urology & Nephrology